



Press release

Date

September 19, 2019

COMCO investigation against pharma suppliers

Berne, September 19, 2019 – The Swiss Competition Commission (COMCO) has opened an investigation against several manufacturers and distributors of active pharmaceutical ingredients. COMCO has conducted several dawn raids.

COMCO suspects that manufacturers and distributors of the active pharmaceutical ingredient Scopolamine Butylbromide have concluded unlawful price and market sharing agreements. There are reasonable grounds to suspect that the undertakings have kept the prices of this pharmaceutical ingredient high and that they have allocated markets. The investigation shall examine whether there are indeed unlawful restrictions of competition.

This pharmaceutical ingredient is used for the production of drugs against spasmodic stomach pains, renal colic and bladder spasms. The manufacturers and distributors of Scopolamine Butylbromide resell this pharmaceutical ingredient to drug manufacturers.

Address for enquiries:

Patrik Ducrey Director	058 464 96 78 079 345 01 44	patrik.ducrey@weko.admin.ch
Olivier Schaller Vice director	058 462 21 23 079 703 80 07	olivier.schaller@weko.admin.ch